European Psychiatry - Volume 41 - April 2017

838 / 916

S834 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S772–S846
Results The sample consisted of 72 inpatients (schizophrenia
55.6%, SZA 20% and cluster A PD 19.4%). The negative and the
general psychopathology scales directly correlated at different
degrees in the three groups (schizophrenia: r = 0.750; P < 0.001;
SZA: r = 0.625, P = 0.006; cluster A PD: r = 0.541, P = 0.046). The
symptom “depression” directly correlated with 5 out of 7 neg-
ative symptoms: blunted affect (r = 0.616, P < 0.001), emotional
withdrawal (r= 0.643, P < 0.001), poor rapport (r= 0.389, P = 0.001),
passive/apathetic social withdrawal ( r= 0.538, P < 0.001), lack of
spontaneity & flow of conversation (r= 0.399, P = 0.001).
Conclusions Our study confirmed the existence of the
“schizophrenia spectrum” with combined different disorders lying
on a continuum in which negative symptoms mainly correlated
with the psychopathological functioning. Noteworthy, the symp-
toms of the negative scale strongly correlatedwith the “depression”
symptom, underlying the impact of the affective symptoms on the
severity of the “schizophrenia spectrum” disorders.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1309
Ultra-resistant schizophrenia and
potentiation strategies
S. Khouadja ∗, R. Ben Soussia , S. Younes , A. Bouallagui , I. Marrag ,
M. Nasr
University Hospital, Psychiatry, Mahdia, Tunisia
∗ Corresponding author.
Introduction Treatment resistance to clozapine is estimated at
40–70% of the treated population. Several clozapine potentiation
strategies have come into clinical practice although often without
evidence-based support.
Objective The aim of our work was to identify the potentiation
strategies in ultra-resistant schizophrenia depending on the sub-
type of schizophrenia.
Methodology This is a prospective study conducted on patients
with the diagnosis of schizophrenia, based on DSM-IV-TR criteria,
and hospitalized in the psychiatric department of the univer-
sity hospital in Mahdia, Tunisia. The study sample consisted of
patients meeting the resistant schizophrenia criteria as defined by
national institute for clinical excellence (NICE), and the prescrip-
tion of clozapine for 6 to 8 weeks was shown without significant
improvement.
Results we have collected 10 patients. The mean serum level
of clozapine was 462.25mg/L. The potentiation strategies were
different depending on the subtype of schizophrenia. For the undif-
ferentiated schizophrenia, we have chosen ECT sessions. For the
disorganized schizophrenia, we opted for amisulpiride and arip-
iprazole. For the paranoid forms, we have chosen the association
of risperidone and ECT. A psychometric improvement was noted in
BPRS ranging from 34 to 40%.
Conclusion Every potentiation strategy entails a cost, whether it
is an additional monetary cost, adverse effects or greater stress to
caregivers. The cost/benefit equation should be thoroughly evalu-
ated and discussed before commencing a strategy.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1310
Increased prevalence of toxoplasma
gondii seropositivity in patients with
treatment-resistant schizophrenia
M. Sagud ∗, S. Vlatkovic , D. Svob Strac , M. Sviben ,
M. Zivkovic , M. Vilibic , B. Vuksan-Cusa , A. Mihaljevic-Peles ,
N. Pivac
1 Psychiatrist, Assistant Professor, School of Medicine, University of
Zagreb, Zagreb, Croatia
2 University Psyciatric Clinic Vrapce, Psychiatry, Zagreb, Croatia
3 Rudjer Boskovic Institute, Laboratory for Molecular
Neuropsychiatry Division of Molecular Medicine, Zagreb, Croatia
4 Croatian National Institute of Public Health, Department of
Parasitology and Mycology, Zagreb, Croatia
5 University Psychiatric Clinic Vrapce, Psychiatry, Zagreb, Croatia
6 School of Medicine, University of Osijek, University Hospital Centre
Zagreb, Psychiatry, Zagreb, Croatia
7 School of Medicine, University of Zagreb, Psychiatry, Zagreb, Croatia
∗ Corresponding author.
Introduction Previous studies suggested that patients with
schizophrenia had an increased prevalence of antibodies against
toxoplasma gondii (TG) and that those seropositive patients had
higher symptom severity. However, there is no data on the rela-
tionship between treatment-resistant schizophrenia (TRS) and TG
seroprevalence.
Objectives To determine the association between TRS and TG
seropositivity, and to further investigate the relationship between
TG seropositivity and different clinical features of schizophrenia.
Methods In this cross-sectional study, we included 210 male
inpatients with schizophrenia. TG seropositivity was determined
by ELFA assay. Treatment-resistance was defined as a failure of at
least 2 adequate anti-psychotic trials. Data were analyzed using 2
test or Mann–Whitney test.
Results The rate of TG seropositivity in the entire sample
was 52.3%, whereas 47.6% of patients met the definition for
treatment-resistance. Seropositive patients had twice the rate of
treatment–resistance compared to seronegative patients (63.6%
vs. 30.0%, P < 0.0001). Moreover, in the seropositive group, the
patients were older (47.6± 12.2 vs. 39.81 ± 12.01 years, P < 0.0001),
had higher number of previous hospitalizations (13.9 ±11.7 vs.
9.6 ±8.5, P = 0.0073), and increased Calgary depression scale for
schizophrenia (CDSS) total score (7.8 ± 4.5 vs. 6.3± 3.8, P = 0.012).
There were no differences between the groups in the age of dis-
ease onset, smoking, positive and negative syndrome scale (PANSS)
total, positive and negative scores, and the life-time history of sui-
cide attempts.
Conclusions Our results support the hypothesis that TG seropos-
itivity might contribute to treatment-resistance in schizophrenia,
at least in male patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1311
From polipharmacy to monotheraphy
a case about schizoaffective disorder
S.F. Salonia ∗, P.E. Asensio Pascual , B. Pérez Molina ,
A.M. García Herrero , M.D.C. Martinez Tomás ,
J. Martinez Martinez , Á.A. Maroto Hernández ,
A.M. Gea Jimenez , F.J. Sanchís Lledó ,
M. Infante Sánchez de Lugarnuevo
1 CSM Yecla, Psychiatry, Yecla, Spain
2 CSM Yecla, Nursing, Yecla, Spain
3 CSM Yecla, Psychology, Yecla, Spain
∗ Corresponding author.
The aim of the present poster is to describe an initial complex case
of schizoaffective disorder with other clinical adverse conditions
(metabolic disorders) in a young adult male, which gradually went
into a positive treatment way from polipharmacy to monotera-
phy. His psychiatric history started when he was 25-year-old, he
was diagnosed of heroine dependence, hypercholesterolemia and
hypertrigliceridemia. In 2000 he had a suicide attempt in a context
of depressive mood and delusions. He needed a psychiatric hospi-
talization for the first time in his life and he received anti-psychotics